Calmark's distributor in India also signs agreements for the Neo products

Calmark's distributor in India also signs agreements for the Neo products

Pressmeddelanden
Press releases
Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with r2 Diagnostics in India regarding Calmark's test for newborns.

As previously announced, Calmark has entered an exclusive distributor agreement with the company r2 Diagnostics regarding marketing and sales of Calmark's COVID19-LDH test in India. This is now being expanded with the Neo products where the first to be launched is Neo-Bilirubin.

Every year, about 25 million children are born in India. Of these, it is estimated that about 30% need to take at least one blood sample to ensure bilirubin levels. Some children need to be tested several times

"It feels very good to get started with Neo-Bilirubin sales in India, where there is a great need for the product. The market for bilirubin blood tests exceeds 7.5 million tests annually," says Magdalena Tharaldsen, Director International Business Development for Calmark. "I am also very happy to be able to extend the agreement with r2 Diagnostics, which already knows Calmark's POC-system!"

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 9 May 2022, 15:50 CEST.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.